Indication: Growth Hormone Deficiency (GHD)
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficiency (GHD)
Sub-indication: Growth Hormone Deficience (GHD)
Study Type: Drug Study
Principal Investigator: Kupper Wintergerst, M.D.Norton Children's Endocrinology, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Lumos Pharma, Inc.
Email for more information: NCRI-Endo@NortonHealthcare.org